Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591
Phone: (914) 847-7000Website: https://www.regeneron.com/Careers: careers.regeneron.com
Latest news
- Regeneron Provides Update on Biologics License Application for Linvoseltamab
20 August 2024 - Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
16 June 2024 - Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
7 April 2024 - Regeneron Provides Update on Biologics License Application for Odronextamab
25 March 2024 - Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
21 February 2024 - Dupixent (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
25 January 2024 - Dupixent (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement
16 January 2024 - Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
10 December 2023 - Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma
7 December 2023 - Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review
29 September 2023
Drugs Associated with Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. manufactures, markets and/or distributes more than 9 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Arcalyst
Generic name: rilonacept Drug class: interleukin inhibitors |
4 reviews | 10 / 10 |
|
Dupixent
Generic name: dupilumab Drug class: interleukin inhibitors |
415 reviews | 7.0 / 10 |
|
Evkeeza
Generic name: evinacumab Drug class: miscellaneous antihyperlipidemic agents |
||
|
Eylea
Generic name: aflibercept Drug class: anti-angiogenic ophthalmic agents |
60 reviews | 7.1 / 10 |
|
Eylea HD
Generic name: aflibercept Drug class: anti-angiogenic ophthalmic agents |
2 reviews | 9.0 / 10 |
|
Kevzara
Generic name: sarilumab Drug class: antirheumatics, interleukin inhibitors |
24 reviews | 6.7 / 10 |
|
Libtayo
Generic name: cemiplimab Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors) |
7 reviews | 8.6 / 10 |
|
Praluent
Generic name: alirocumab Drug class: PCSK9 inhibitors |
263 reviews | 6.4 / 10 |
|
Veopoz
Generic name: pozelimab Drug class: selective immunosuppressants |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||